A cerebrospinal fluid microRNA signature as biomarker for glioblastoma

Akers, Johnny; Hua, Wei; Li, Hongying; Ramakrishnan, Valya; Yang, Zixiao; Quan, Kai; Zhu, Wei; Li, Jie; Figueroa, Javier; Hirshman, Brian R.; Miller, Brittney; Piccioni, David; Ringel, Florian; Komotar, Ricardo J.; Messer, Karen; Galasko, Douglas; Hochberg, Fred H.; Mao, Ying; Carter, Bob S.; Chen, Clark C.

doi:10.18632/oncotarget.18332

Cited by 119 publications

(101 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Subsequently, we assessed the remaining 254 full‐text articles and excluded 226 studies based on the exclusion criteria, including 30 meetings, and 196 without clinical data to make a 2 × 2 contingency table. In total, 28 studies were ultimately included in this study . A flowchart of the selection process for this study is presented in Figure .…”

Section: Resultsmentioning

confidence: 99%

“…In total, 28 studies were ultimately included in this study. 6,9, A flowchart of the selection process for this study is presented in Figure 1.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…7 Ma et al 8 analyzed only the expression of miRNAs in blood samples. However, Akers et al 9 reported that miRNAs in CSF could serve as biomarkers for glioma. Moreover, new studies of miRNAs have been done since the publication of the meta-analyses of Qu et al 7 4 years ago.…”

mentioning

confidence: 99%

See 2 more Smart Citations

MicroRNAs as potential biomarkers for the diagnosis of glioma: A systematic review and meta‐analysis

et al. 2018

View full text Add to dashboard Cite

Glioma is the most common central nervous system tumor and associated with poor prognosis. Identifying effective diagnostic biomarkers for glioma is particularly important in order to guide optimizing treatment. MicroRNAs (miRNAs) have drawn much attention because of their diagnostic value in diverse cancers, including glioma. We summarized studies to identify the potential diagnostic values of miRNAs in glioma patients. We included articles reporting miRNAs for differentiation of glioma patients from controls. We calculated sensitivities, specificities, and area under the curves (AUC) of individual miRNA and miRNA panels. We found that overall sensitivity, specificity, and AUC of miRNAs in diagnosis of glioma were 85% (95% confidence interval [CI]: 0.81‐0.89), 90% (95% CI 0.85‐0.93), and 93% (95% CI 0.91‐0.95), respectively. Meta‐regression analysis showed that the detection of miRNAs expression in cerebrospinal fluid (CSF) and brain tissue largely improved the diagnostic accuracy. Likewise, panels of multiple miRNAs could enhance the pooled sensitivity. Moreover, AUC of miR‐21 was 0.88, with 86% sensitivity and 94% specificity. This study demonstrated that miRNAs could function as potential diagnosis markers in glioma. Detection of miRNAs in CSF and brain tissue displays high accuracy in the diagnosis of glioma.

show abstract

Section: Resultsmentioning

confidence: 99%

“…In total, 28 studies were ultimately included in this study. 6,9, A flowchart of the selection process for this study is presented in Figure 1.…”

Section: Study Characteristicsmentioning

confidence: 99%

See 1 more Smart Citation

MicroRNAs as potential biomarkers for the diagnosis of glioma: A systematic review and meta‐analysis

et al. 2018

View full text Add to dashboard Cite

show abstract

“…and be exploited as non-invasive biomarkers for glioma detection. [5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24] However, there have been differentials or inconformity among these studies concerning the reliability and application of miRNAs for the early non-invasive detection of glioma. Therefore, we carried out this meta-analysis to further comprehensively expound the diagnostic value of cell-free miRNAs in early glioma detection based on the former studies.…”

Section: Introductionmentioning

confidence: 99%

Cell-free microRNAs as non-invasive biomarkers in glioma: a diagnostic meta-analysis

Che

Zhang

2019

Int J Biol Markers

View full text Add to dashboard Cite

Objective: Since the diagnostic value of microRNAs for detecting glioma is contentious, we aimed to carry out a metaanalysis to synthetically evaluate the diagnostic significance of cell-free microRNAs in cerebrospinal fluid and blood in the detection of glioma. Methods: A systematic document retrieval of public databases was performed to obtain eligible studies. Specificity was applied to draw the summary receiver operator characteristic (SROC) curve against sensitivity, and the pooled diagnostic efficiency was assessed by generating the area under the SROC curve. Meta-regression and subgroup analyses were utilized to explore the latent sources of heterogeneity. STATA 12.0, RevMan 5.3 and Meta-DiSc 1.4 were used to conduct all statistical analyses. Results: A total of 47 studies from 20 articles comprising 2262 glioma patients and 1986 controls were included in our meta-analysis. Cell-free microRNAs exhibited relatively good diagnostic efficiency in glioma detection, with a sensitivity of 0.83, a specificity of 0.87, and an area under the curve of 0.91. Cell-free miR-21 performed best with pooled area under the curve of 0.88, followed by miR-125 and miR-222. Subgroup analyses and meta-regression indicated that there was substantial heterogeneity existing among the studies, which was in part caused by sample size, World Health Organization grade, reference gene, microRNA origin (extracellular vesicles or non-extracellular vesicle-based-microRNA), microRNA profiling (single-or multiple-microRNA), specimen types, and ethnicity. Conclusions: Cell-free microRNAs in cerebrospinal fluid and blood may play an important role as promising noninvasive biomarkers in the early diagnosis of glioma. Further comprehensive forward-looking research is required to validate their clinical significance in glioma diagnosis.

show abstract

“…Most available data relate to diffuse glioma, in particular glioblastoma, and a broad range of miRNAs have been investigated, alone or in specific combinations, as possible diagnostic or prognostic biomarkers . Both CSF and blood [] have been evaluated as sources of genetic material. The possibility of distinguishing between primary and secondary CNS tumours by miRNA profiling, and of estimating patients’ outcome based on their concentrations has been suggested.…”

Section: Circulating Cell‐free Nucleic Acids Analysismentioning

confidence: 99%

Review: Peering through a keyhole: liquid biopsy in primary and metastatic central nervous system tumours

Bertero

Siravegna

Rudà

et al. 2019

Neuropathology Appl Neurobio

View full text Add to dashboard Cite

2019) Neuropathology and Applied Neurobiology 45, 655-670 Peering through a keyhole: liquid biopsy in primary and metastatic central nervous system tumours Tumour molecular profiling by liquid biopsy is being investigated for a wide range of research and clinical purposes. The possibility of repeatedly interrogating the tumour profile using minimally invasive procedures is helping to understand spatial and temporal tumour heterogeneity, and to shed a light on mechanisms of resistance to targeted therapies. Moreover, this approach has been already implemented in clinical practice to address specific decisions regarding patients' follow-up and therapeutic management. For central nervous system (CNS) tumours, molecular profiling is particularly relevant for the proper characterization of primary neoplasms, while CNS metastases can significantly diverge from primary disease or extra-CNS metastases, thus compelling a dedicated assessment. Based on these considerations, effective liquid biopsy tools for CNS tumours are highly warranted and a significant amount of data have been accrued over the last few years. These results have shown that liquid biopsy can provide clinically meaningful information about both primary and metastatic CNS tumours, but specific considerations must be taken into account, for example, when choosing the source of liquid biopsy. Nevertheless, this approach is especially attractive for CNS tumours, as repeated tumour sampling is not feasible. The aim of our review was to thoroughly report the state-of-the-art regarding the opportunities and challenges posed by liquid biopsy in both primary and secondary CNS tumours.

show abstract

A cerebrospinal fluid microRNA signature as biomarker for glioblastoma

Cited by 119 publications

References 39 publications

MicroRNAs as potential biomarkers for the diagnosis of glioma: A systematic review and meta‐analysis

MicroRNAs as potential biomarkers for the diagnosis of glioma: A systematic review and meta‐analysis

Cell-free microRNAs as non-invasive biomarkers in glioma: a diagnostic meta-analysis

Review: Peering through a keyhole: liquid biopsy in primary and metastatic central nervous system tumours

Contact Info

Product

Resources

About